Nanobiotix Valuation
| NANO Stock | EUR 3.22 0.11 3.30% |
At this time, the firm appears to be overvalued. Nanobiotix SA secures a last-minute Real Value of €2.8 per share. The latest price of the firm is €3.22. Our model forecasts the value of Nanobiotix SA from analyzing the firm fundamentals such as Shares Outstanding of 34.88 M, return on equity of -1.99, and Operating Margin of (17.96) % as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Nanobiotix's price fluctuation is relatively risky at this time. Calculation of the real value of Nanobiotix SA is based on 3 months time horizon. Increasing Nanobiotix's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Nanobiotix is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Nanobiotix Stock. However, Nanobiotix's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 3.22 | Real 2.8 | Hype 3.33 |
The real value of Nanobiotix Stock, also known as its intrinsic value, is the underlying worth of Nanobiotix SA Company, which is reflected in its stock price. It is based on Nanobiotix's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Nanobiotix's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Nanobiotix SA helps investors to forecast how Nanobiotix stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Nanobiotix more accurately as focusing exclusively on Nanobiotix's fundamentals will not take into account other important factors: Nanobiotix Total Value Analysis
Nanobiotix SA is now forecasted to have takeover price of 111.08 M with market capitalization of 115.07 M, debt of 35.56 M, and cash on hands of 36.2 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Nanobiotix fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
111.08 M | 115.07 M | 35.56 M | 36.2 M |
Nanobiotix Investor Information
About 26.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 1.2. Nanobiotix SA had not issued any dividends in recent years. The entity had 1179:1078 split on the 25th of February 2014. Based on the key measurements obtained from Nanobiotix's financial statements, Nanobiotix SA is not in a good financial situation at the moment. It has a very high risk of going through financial straits in December.Nanobiotix Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Nanobiotix has an asset utilization ratio of 0.009826 percent. This suggests that the Company is making €9.8E-5 for each dollar of assets. An increasing asset utilization means that Nanobiotix SA is more efficient with each dollar of assets it utilizes for everyday operations.Nanobiotix Ownership Allocation
Nanobiotix SA maintains a total of 34.88 Million outstanding shares. Nanobiotix SA secures 3.78 % of its outstanding shares held by insiders and 25.56 % owned by institutional investors. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Nanobiotix Profitability Analysis
The company reported the revenue of 10 K. Net Loss for the year was (47 M) with profit before overhead, payroll, taxes, and interest of 2.65 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Nanobiotix's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Nanobiotix and how it compares across the competition.
About Nanobiotix Valuation
The stock valuation mechanism determines Nanobiotix's current worth on a weekly basis. Our valuation model uses a comparative analysis of Nanobiotix. We calculate exposure to Nanobiotix's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Nanobiotix's related companies.Nanobiotix SA, a late stage clinical company, develops and sells nanomedicine for the treatment of cancer worldwide. Nanobiotix SA was incorporated in 2003 and is headquartered in Paris, France. NANOBIOTIX operates under Drug Manufacturers - Major classification in France and is traded on Paris Stock Exchange. It employs 102 people.
8 Steps to conduct Nanobiotix's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Nanobiotix's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Nanobiotix's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Nanobiotix's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Nanobiotix's revenue streams: Identify Nanobiotix's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Nanobiotix's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Nanobiotix's growth potential: Evaluate Nanobiotix's management, business model, and growth potential.
- Determine Nanobiotix's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Nanobiotix's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Complementary Tools for Nanobiotix Stock analysis
When running Nanobiotix's price analysis, check to measure Nanobiotix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nanobiotix is operating at the current time. Most of Nanobiotix's value examination focuses on studying past and present price action to predict the probability of Nanobiotix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nanobiotix's price. Additionally, you may evaluate how the addition of Nanobiotix to your portfolios can decrease your overall portfolio volatility.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |